Navigation Links
US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

New Indications and Products Offset Patent Expirations

SAN FRANCISCO, Sept. 11 /PRNewswire/ -- The U.S. market for drug treatment of major neuropathic pain (NP) conditions is currently valued at $2.6 billion, according to US Neuropathic Pain, a report released today by WWMR, Inc. Growth over the past four years has been driven largely by the successful launch of Lyrica (pregabalin) for diabetic neuropathic pain and post-herpetic neuralgia in December 2004 along with its 2007 approval for fibromyalgia, as well as the launch of Lilly's Cymbalta (duloxetine) for diabetic neuropathic pain in 2004. The additional June 2008 approval of Cymbalta for fibromyalgia will spur penetration of this prevalent condition.

Based on a decade of experience tracking and forecasting the NP Market, WWMR predicts healthy growth over the next 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit of an additional mechanism of action. Growth will slow between 2013 and 2018 as Lyrica and Cymbalta patents expire, and the fibromyalgia market penetration becomes saturated. Additional launch of novel compounds and new brands of existing drug classes will be required in order to sustain market growth.

The US neuropathic pain market consists of 4.7 million patients, and is expected to grow to more than 6.1 million patients, and be valued at $5.1 billion in 2018. With the addition of two key new indications to this report (Fibromyalgia and Neuropathic Cancer Pain) patient population estimates and projections as well as market value and projections, are available for a total of ten Neuropathic Pain Conditions (neuropathic back pain, fibromyalgia, diabetic neuropathy, neuropathic cancer pain, complex regional pain syndrome, HIV/AIDS neuropathy, post-herpetic neuralgia, phantom limb pain, spinal cord injury, and trigeminal neuralgia). Insights have also been added from WWMR's US Pain Clinic Monitor -- an audit of more than 100 pain clinics containing prescribing and condition details on more than 5000 patients -- many of whom have neuropathic pain.

Worldwide, approximately 76 agents are in active clinical trials for the treatment of neuropathic pain, and are reviewed in this report. Five new neuropathic pain treatments are currently registered or pre-registered with the FDA for NP marketing approval: lacosamide (Schwarz Pharma), milnacipran (Forest Laboratories/Cypress Bioscience), transdermal capsaicin (NeurogesX) and a dual cannabinoid receptor agonist (GW/Bayer), and fentanyl buccal (Cephalon). Eighteen drugs are in Phase III development in the US including two GABA receptor agonists pregabalin (Pfizer) and gabapentin GR (Depomed); a sodium channel antagonist mexiletine (Boehringer Ingelheim); three glutamate / NMDA antagonists ketamine intranasal (Javelin), a dextromethorphan/quinidine combination (Avanir), and NP-1 (EpiCept/Epitome); two serotonin/norepinephrine reuptake inhibitors desvenlafaxine (Wyeth), and paroxetine (GSK/Novo Nordisk); an alpha-2 adrenergic receptor antagonist/norepinehrine reuptake inhibitor reboxetine (Pfizer); an opioid receptor agonist/norepinephrine reuptake inhibitor tapentadol (Ortho-McNeil); a dopamine receptor agonist sodium oxybate (Jazz), and a neuromuscular blocking agent botulinum toxin A (Allergan). Early-phase products are also described in the full report.


-- US Pain Clinic Monitor (available now)

-- 2008 European Neuropathic Pain (coming soon)

-- 2008 Japanese Neuropathic Pain (coming soon)

WWMR, Inc. is a leader in Pain Reporting, and also designs and executes research which brings clarity, reveals innovative opportunities and provides deeper understanding across many therapy areas and all phases of drug development. This enables our clients to:
-- Demonstrate the commercial value of product/partnering opportunities

-- Optimize the revenue potential of their product portfolio

-- Identify and evaluate additional business opportunities


A highly-regarded marketing research and strategic consulting firm with global capabilities. Since 1994, WWMR has provided thousands of insightful, proprietary studies to pharmaceutical, biotech, medical device, and diagnostics companies worldwide. Using primary and secondary research methodologies, WWMR provides insights on current and emerging markets using their expertise in product and technology assessments, forecast modeling, epidemiology projections, product launch monitoring (pre- and post-), primary marketing research and medical economic analyses.

For more information, contact:

Michelle Nordstrom

WWMR, Inc.

2929 Campus Drive

Suite 200

San Mateo, CA 94403

Phone: (888) 947-2339

(650) 513-0300

Fax: (650) 312-1570



Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
3. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
4. US Facet Fixation Market to Increase by Over 60% Annually Through 2012
5. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
6. Injectable CTM Manufacturing Market Report Now Available
7. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
8. Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Filter Markets - Discover the Growth Segments
10. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Culprits beware, a University ... professor Jan Halámek, is taking crime scene fingerprint ...   -->   ... --> --> Halámek ... discovered a straightforward concept for identifying whether a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and ... The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately ... several North American tour dates. The Exhibition is based on Universal Pictures’ Jurassic ...
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... to adding an additional independent director, and the Company ... investigation of allegations in a recent anonymous internet report ... on both initiatives. Linda Powers stated, ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
Breaking Biology News(10 mins):